• 1_Accelero_Autumn2018.jpg
  • 2_Accelero_Autumn2018.jpg
  • 3_Accelero_Autumn2018.jpg
  • 4_Accelero_Autumn2018.jpg

To download the press release, please click here.

 

Accelero Initiates Clinical Study to Collect Human Wound Fluid

Berlin, 16 September 2018

The company is pleased to initiate its first formal clinical study at one of the breast cancer centres in Berlin, Germany. The study is entitled “Post-operative wound fluid collected from female breast cancer patients” and has been approved by the clinical ethics committee.

This is the first time Accelero has been setting up a clinical study. A Berlin-based breast cancer centre has been contracted to provide human wound fluid for bioanalytical purposes. This will enable Accelero to support clients developing therapeutics for wound healing.

Accelero Bioanalytics GmbH is a GLP certified contract research service provider for regulatory drug development and maintains genetic engineering (bio)safety level 2 laboratories in compliance with ICH GCP regulations.

The business model focuses on – but is not limited to – the development of allogenic Advanced Therapy Medicinal Products (ATMP) in a regulatory context. The team provides bioanalytical support for living biotherapeutics (human cells, microbial cells), viruses (oncolytic, adeno-associated vectors, etc) or vaccines (DNA, plasmids, etc).

For additonal information on our services please feel free to use our contact form or send us an email to service(at)accelero-bioanalytics.com. The Accelero team will be happy to assist you.